1. Drolet DW, Green LS, Gold L, Janjic N (2016) Fit for the eye: aptamers in ocular disorders. Nucleic Acid Ther 26(3):127–146
2. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Mones J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC (2017) Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter. Randomized Controlled Trial Ophthalmol 124(2):224–234
3. Mousa SA, Mousa SS (2010) Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 24(3):183–194
4. Barakat MR, Kaiser PK (2009) VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18(5):637–646
5. Chakravarthy U, Adamis AP, Cunningham ET, Jr., Goldbaum M, Guyer DR, Katz B, Patel M (2006) Neovascularization (V.I.S.I.O.N.) clinical trial group, year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113 (9):1508 (e01–e25)